Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.

A. Seki, M. Yoshinouchi, N. Seki, J. Kodama, Y. Miyagi, T. Kudo

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We examined gene amplifications of the c-erbB-2 and FGF-3 gene in 48 epithelial ovarian cancers by differential PCR and addressed their association with clinico-pathological features including clinical outcome. Overall, 25.0 and 20.8% of ovarian cancers displayed amplified c-erbB-2 or FGF-3 gene, respectively. Amplification of the c-erbB-2 gene was significantly associated with particular histological cell types, higher histological grade, and low levels of serous CA125. However, there was no correlation between c-erbB-2 gene amplification and patient outcome. No correlation was observed between FGF-3 gene amplification and any clinico-pathological features including overall survival. These findings suggested that c-erbB-2 or FGF-3 gene amplification might be one of the oncogenic events implicated in the development of ovarian cancers, yet is not a useful prognostic marker.

Original languageEnglish
Pages (from-to)103-106
Number of pages4
JournalInternational Journal of Oncology
Volume17
Issue number1
Publication statusPublished - Jul 2000

Fingerprint

Gene Amplification
Fibroblast Growth Factor 2
erbB-2 Genes
Ovarian Neoplasms
Genes
Polymerase Chain Reaction
Survival
iodonitrotetrazolium
Ovarian epithelial cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Seki, A., Yoshinouchi, M., Seki, N., Kodama, J., Miyagi, Y., & Kudo, T. (2000). Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. International Journal of Oncology, 17(1), 103-106.

Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. / Seki, A.; Yoshinouchi, M.; Seki, N.; Kodama, J.; Miyagi, Y.; Kudo, T.

In: International Journal of Oncology, Vol. 17, No. 1, 07.2000, p. 103-106.

Research output: Contribution to journalArticle

Seki, A, Yoshinouchi, M, Seki, N, Kodama, J, Miyagi, Y & Kudo, T 2000, 'Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.', International Journal of Oncology, vol. 17, no. 1, pp. 103-106.
Seki A, Yoshinouchi M, Seki N, Kodama J, Miyagi Y, Kudo T. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. International Journal of Oncology. 2000 Jul;17(1):103-106.
Seki, A. ; Yoshinouchi, M. ; Seki, N. ; Kodama, J. ; Miyagi, Y. ; Kudo, T. / Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. In: International Journal of Oncology. 2000 ; Vol. 17, No. 1. pp. 103-106.
@article{48805ea3f725435a978e9c29851a9387,
title = "Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.",
abstract = "We examined gene amplifications of the c-erbB-2 and FGF-3 gene in 48 epithelial ovarian cancers by differential PCR and addressed their association with clinico-pathological features including clinical outcome. Overall, 25.0 and 20.8{\%} of ovarian cancers displayed amplified c-erbB-2 or FGF-3 gene, respectively. Amplification of the c-erbB-2 gene was significantly associated with particular histological cell types, higher histological grade, and low levels of serous CA125. However, there was no correlation between c-erbB-2 gene amplification and patient outcome. No correlation was observed between FGF-3 gene amplification and any clinico-pathological features including overall survival. These findings suggested that c-erbB-2 or FGF-3 gene amplification might be one of the oncogenic events implicated in the development of ovarian cancers, yet is not a useful prognostic marker.",
author = "A. Seki and M. Yoshinouchi and N. Seki and J. Kodama and Y. Miyagi and T. Kudo",
year = "2000",
month = "7",
language = "English",
volume = "17",
pages = "103--106",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.

AU - Seki, A.

AU - Yoshinouchi, M.

AU - Seki, N.

AU - Kodama, J.

AU - Miyagi, Y.

AU - Kudo, T.

PY - 2000/7

Y1 - 2000/7

N2 - We examined gene amplifications of the c-erbB-2 and FGF-3 gene in 48 epithelial ovarian cancers by differential PCR and addressed their association with clinico-pathological features including clinical outcome. Overall, 25.0 and 20.8% of ovarian cancers displayed amplified c-erbB-2 or FGF-3 gene, respectively. Amplification of the c-erbB-2 gene was significantly associated with particular histological cell types, higher histological grade, and low levels of serous CA125. However, there was no correlation between c-erbB-2 gene amplification and patient outcome. No correlation was observed between FGF-3 gene amplification and any clinico-pathological features including overall survival. These findings suggested that c-erbB-2 or FGF-3 gene amplification might be one of the oncogenic events implicated in the development of ovarian cancers, yet is not a useful prognostic marker.

AB - We examined gene amplifications of the c-erbB-2 and FGF-3 gene in 48 epithelial ovarian cancers by differential PCR and addressed their association with clinico-pathological features including clinical outcome. Overall, 25.0 and 20.8% of ovarian cancers displayed amplified c-erbB-2 or FGF-3 gene, respectively. Amplification of the c-erbB-2 gene was significantly associated with particular histological cell types, higher histological grade, and low levels of serous CA125. However, there was no correlation between c-erbB-2 gene amplification and patient outcome. No correlation was observed between FGF-3 gene amplification and any clinico-pathological features including overall survival. These findings suggested that c-erbB-2 or FGF-3 gene amplification might be one of the oncogenic events implicated in the development of ovarian cancers, yet is not a useful prognostic marker.

UR - http://www.scopus.com/inward/record.url?scp=0034220881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034220881&partnerID=8YFLogxK

M3 - Article

C2 - 10853025

AN - SCOPUS:0034220881

VL - 17

SP - 103

EP - 106

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -